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Abstract
Genome-wide association studies (GWAS) for Autism Spectrum Disorder (ASD) thus far met limited success in the
identification of common risk variants, consistent with the notion that variants with small individual effects cannot be
detected individually in single SNP analysis. To further capture disease risk gene information from ASD association studies,
we applied a network-based strategy to the Autism Genome Project (AGP) and the Autism Genetics Resource Exchange
GWAS datasets, combining family-based association data with Human Protein-Protein interaction (PPI) data. Our analysis
showed that autism-associated proteins at higher than conventional levels of significance (P,0.1) directly interact more
than random expectation and are involved in a limited number of interconnected biological processes, indicating that they
are functionally related. The functionally coherent networks generated by this approach contain ASD-relevant disease
biology, as demonstrated by an improved positive predictive value and sensitivity in retrieving known ASD candidate genes
relative to the top associated genes from either GWAS, as well as a higher gene overlap between the two ASD datasets.
Analysis of the intersection between the networks obtained from the two ASD GWAS and six unrelated disease datasets
identified fourteen genes exclusively present in the ASD networks. These are mostly novel genes involved in abnormal
nervous system phenotypes in animal models, and in fundamental biological processes previously implicated in ASD, such
as axon guidance, cell adhesion or cytoskeleton organization. Overall, our results highlighted novel susceptibility genes
previously hidden within GWAS statistical ‘‘noise’’ that warrant further analysis for causal variants.
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Introduction
Autism Spectrum Disorder (ASD) is a complex neurodevelop-
mental illness with significant clinical and genetic heterogeneity.
Family and twin studies demonstrated that ASD is one of the most
heritable neuropsychiatric disorders, but there is yet no consensus
on the underlying genetic architecture [1,2]: while single-gene
disorders, metabolic disorders and Copy Number Variants (CNVs)
account for approximately 30% of the etiology of ASD [1,3–7],
the contribution of common risk variants to the remaining
heritability is still unclear. Thus far, each large genome-wide
association study (GWAS) carried out for ASD highlighted a
single, non-overlapping locus [8–11], which frequently was not
replicated by subsequent independent replication studies [12].
Devlin et al. (2011) have recently predicted that common
variants having an odds ratio of 1.5 or more are very unlikely to
exist; few, if any, common variants with an impact on risk
exceeding 1.2 may still await discovery, but require much larger
sample sizes, while variants with modest impact may range from
zero to many thousands [13]. The small effect of common risk
variants for ASD represents a challenge for their individual
detection using conventional single-marker association analysis,
which likely allows many true loci to remain hidden within the
GWAS statistical ‘‘noise’’. Evidence from classical quantitative
genetic analysis further suggests that most of the heritability
missing in complex diseases is rather hidden below the threshold
for genome-wide significant associations [14,15].
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e112399
New strategies are therefore needed to increase the power of
GWAS analysis. The use of molecular networks, which is not
limited by a priori sorting the genes into incompletely annotated
predefined gene sets, is emerging as an appealing unbiased
alternative to pathway analysis. Network-based approaches have
been widely applied in the analysis of high-throughput expression
data from a wide range of diseases [16] and have proven successful
in the identification of subnetwork markers more reproducible and
with a higher prediction performance than individual markers
[17]. More recent studies incorporated protein networks into the
analysis of genome-wide association data, using networks to search
for interacting loci in human GWAS data [18,19] or to identify
genome wide-enriched pathways [20–24]. However, an unsuper-
vised global network analysis of ASD GWAS data that includes all
signals without arbitrary significance thresholds has not been
performed, and may lead to the identification of many risk variants
of small effect below the accepted threshold for statistical
significance.
Based on the premise that disease-causing genes are likely to be
functionally related, in the present study we applied a network-
based approach to two ASD GWAS datasets, the AGP consortium
GWAS and the GWAS carried out in the Autism Genetic
Resource Exchange (AGRE) dataset [10]. For this purpose we
integrated genome wide association data with Human Protein-
Protein interaction data and examined topological network
properties indicative of connectivity at various levels of association,
confirming our hypothesis that genes associated to ASD at a
‘‘statistical noise’’ level are functionally connected beyond random
expectation. We compared the enrichment in known ASD
candidates of network genes versus top GWAS genes, and the
overlap of network genes vs the overlap at gene or SNP level
between the two ASD datasets. The network obtained was further
tested for ASD specificity using networks derived from six
unrelated diseases GWAS, and explored for biological processes
associated with ASD.
Materials and Methods
A workflow of the strategy for network definition, validation and
identification of the most relevant candidate genes is shown in
Figure 1.
Ethics statement
All the data used is previously published and publicly available.
Written informed consent has been previously obtained from all
families and procedures had approval from institutional review
boards from all the institutions involved in recruitment and
research, following national and international ethical and legal
regulations and the principles of the Declaration of Helsinki.
Datasets
The AGP dataset included 2818 trios consisting of autistic
patients and both parents collected as part of the AGP
Consortium. Patients were diagnosed and genotyped as previously
reported [8]. Written informed consent was obtained from all
families and procedures had approval from institutional review
boards [8]. A total of 723 423 SNPs meeting the QC criteria [9],
genotyped in 8491 individuals, were tested for association using
the Transmissions Disequilibrium Test (TDT) implemented in
PLINK v1.07 [25].
The GWAS replication dataset from the Autism Genetic
Resource Exchange (AGRE) included 943 ASD families (4,444
subjects) from the AGRE cohort [10]. SNP genotyping data was
obtained from AGRE [10]. Analysis in this study was limited to
SNPs in common with the AGP GWAS and meeting the same QC
criteria (425 587 SNPs).
Summary SNP association results were obtained from the
database of Genotype and Phenotype (dbGAP) repository for 6
case-control GWAS for other pathologies, including Parkinson’s
Disease (PD) [26], Systemic Lupus Erythematosus (SLE) [27],
Multiple Sclerosis (MS) [28], Type 1 Diabetes (T1D) [29], Breast
Cancer (BC) [30] and Neuroblastoma (NB) [31] (Table S1). All
individuals included were of European ancestry and the sample
size was as similar as possible to the replication ASD dataset
(AGRE).
Integration of gene association data with Protein-Protein
interaction data
Genotyped SNPs from the AGP and AGRE GWAS were
assigned to specific genes if they were located within or up to 10 kb
from the gene, using the GRCh37/hg19 genome build (Step 1).
Each gene was assigned a gene score using MAGENTA (Meta-
analysis Gene-set Enrichment of variant associations) [32], which
allocates to each gene the most significant P-value among the
TDT P-values of all individual SNPs mapped to that gene.
MAGENTA then uses step-wise multivariate linear regression
analysis to regress out of this P-value the confounding effects of
gene size, number of SNPs per kilobase (kb), number of
independent SNPs, number of recombination hotspots and the
number of linkage disequilibrium units per kb.
Genes selected at various gene-wise P-value cutoffs (0.5,
-LogP,5) were superimposed onto their corresponding protein on
a large human protein-protein interaction (PPI) network, convert-
ing Entrez gene IDs to Uniprot IDs (release 2010_04) (Step 2).
This PPI network, covering 12372 proteins and 58365 interac-
tions, was previously built compacting data from six public PPI
databases: BIND, BioGRID, HPRD, IntAct, MINT and MPPI
[33–40].
PPI network analysis
Topological properties from the resulting network were
analyzed to select the gene-wise P-value for which corresponding
proteins were functionally connected beyond random expectation,
thus the lowest gene-wise P-value for which there is still relevant
biological data in the GWAS that can be captured through
network analysis (step 3). Three metrics indicative of this
functional coherence were estimated for various association
gene-wise P-value thresholds, for the two ASD datasets, and
compared with those determined for 1000 equal size sets of
randomly selected proteins from the human PPI network. The
metrics evaluated were 1) the percentage of proteins directly
interacting; 2) the percentage of isolated nodes, which represents
the fraction of selected proteins with no interactions with any other
selected protein; and 3) the size of the largest connected
component (LCC), the largest group of selected proteins that are
reachable from each other in the network. An empirical P-value
was obtained computing the fraction of random samples where the
value of the network metric is greater (or smaller in the case of
isolates) than the observed one. Network analysis was performed
using python module Network X.
Performance against a candidate gene list and overlap
between datasets
To evaluate the performance of the proteins included in the
LCC in retrieving known ASD candidate genes, the precision and
recall against a curated list of ASD candidate genes were
calculated (step 4). This list was obtained from SFARIGene and
Network-Based Analysis of ASD GWAS
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e112399
includes 236 genes having at least minimal evidence of association
with ASD (categories 1 to 4) or categorized as syndromic (https://
gene.sfari.org/autdb/Welcome.do).
Precision (Positive Predictive value) is the proportion of known
candidate genes among the selected genes, while recall (Sensitivity)
is the proportion of known candidate genes retrieved by the
Figure 1. Workflow of the strategy for network definition, validation and identification of most relevant candidate genes.
doi:10.1371/journal.pone.0112399.g001
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selection. The precision and recall calculated for the genes
encoding LCC proteins were compared to those determined using
two other gene selection criteria: a) all genes selected at the same
gene P-value cutoff used to derive LCC; b) the same number of
top genes (ranked according to gene-wise P-values) as those
included in the LCC.
Overlap between the AGP and AGRE datasets at SNP, gene
and LCC levels was determined using the Jaccard index, defined
as the size of the intersection divided by the size of the union of the
datasets. For comparison purposes the size of each dataset LCC
was used to select from each GWAS dataset an equal number of
top SNPs (ranked by their TDT P-value) and top genes (ranked by
their gene-wise P-value).
Gene ranking and functional enrichment
To rank ASD-associated proteins included in the AGP LCC by
ASD specificity and reproducibility, a prioritization system was
created, assigning a score to each protein based on their presence
in the LCC derived from the AGRE ASD replication dataset and
from each of the six unrelated disease datasets (step 5). Each
protein included in the AGP LCC had an initial score of 0.5. If the
protein was present in the AGRE ASD dataset LCC, 0.5 was
added to the initial protein score, whereas for each unrelated
disease dataset LCC where the protein was present, one sixth of
0.5 was subtracted from the score. Therefore, protein scores vary
between 0 and 1, with zero representing a protein present in the
LCCs of the AGP dataset and the 6 unrelated diseases, while a
score of 1 is attributed to a protein present only in the LCCs of
both ASD datasets.
Functional enrichment was tested by DAVID (The Database for
Annotation, Visualization and Integrated Discovery 2008_ver-
sion6th; http://david.abcc.ncifcrf.gov) [41,42], a publicly available
bioinformatics tool that identifies functionally related groups of
genes. Overrepresentation of mouse-mutant phenotypes was
evaluated using the web tool MamPhea [43]. The complete list
of the genes in the PPI network was used as background and P-
values were corrected by the Benjamini correction. Top-scoring
genes were further investigated using NextBio platform (Cuper-
tino, CA, USA), a curated and correlated repository of experi-
mental data derived from an extensive set of public resources (eg.
ArrayExpress and GEO) [44]. Protein-protein networks were
visualized in Cytoscape [45].
Results
Genes associated to ASD at P,0.1 are functionally
related
Transmission Disequilibrium Tests were initially carried out in
parallel for the AGP and AGRE datasets to identify small effect
risk variants. In the sample of 2818 AGP families, single SNP
transmission disequilibrium tests of the 723423 SNPs meeting the
QC criteria showed no SNPs reaching the threshold for genome-
wide significance. Two SNPs showed association signals at P,
161026 and very few exceeded P,161025. In the AGRE
dataset, after a similar quality control protocol and using only
SNPs common to both datasets, three SNPs located in regions with
no overlap with the AGP top findings showed association at P,
161026. Given the dearth of meaningful results from these two
GWAS efforts, we proceeded with a network analysis strategy.
The first step involved calculating gene-wise association P-
values corrected for gene size and linkage disequilibrium, taking
into account only the SNPs mapping within 10kb from each gene
(403360 SNPs), followed by the integration of GWAS data onto
protein interaction data. Then, we determined the lowest gene-
wise P-value threshold for which genes encoding the network
proteins were functionally related, inferred by their proximity in
the network. Statistical noise is expected to have random
connections in the network, while disease proteins are more likely
to establish direct interactions between them and more rarely be
isolated in the network, translating into a larger group of proteins
that are all interconnected. For both ASD datasets, proteins
encoded by genes selected at a gene-wise -Log10P cutoff between
0.5 and 1.5 were found to establish significantly more direct
interactions than equal sized sets of randomly selected proteins
(Empirical P values 0.001,P,0.043), with the significance
maintained up to -Log10P=22.0 in the case of AGRE dataset
(Figure S1, Figure 2A). The number of isolated nodes was found to
be significantly smaller in sets of ASD-associated proteins at the
same range of gene-wise -Log10P-values than in random sets
(Empirical P values 0.001,P,0.038), again with significant
differences maintained for lower gene-wise P-values in the AGRE
dataset (Figure S1, Figure 2A). When compared to the same
number of random proteins from the network, proteins encoded
by genes selected at a gene-wise -Log10P,1 from either ASD
dataset are interconnected in a significantly larger LCC (Empirical
P values 0.001,P,0.007) (Figure S1, Figure 2B). The large size
of the largest connected components, 416 and 367 proteins for the
AGP and AGRE datasets, respectively, indicates the existence of
several small effect risk genes reinforcing the high genetic
heterogeneity in ASD.
Based on the lowest gene-wise P-value for which the percentage
of direct interactions was significantly higher, the percentage of
isolated nodes significantly smaller and the size of the LCC
significantly larger than random expectation (Figure 2A and B),
we established gene-wise -Log10P=1 as the cutoff value to infer
functional coherence from the two ASD datasets.
The overall results indicate that, as hypothesized, genes
associated with ASD at the range of GWAS statistical noise
encode proteins that are functionally related and preferentially
directly interact, confirming our expectation that there is indeed
unexplored relevant biology at this statistical level.
Functionally coherent sub networks associated with ASD
contain relevant ASD biology
To test whether the identified groups of functionally connected
proteins captured by the largest connected components indeed
contain ASD-relevant biology, we compared the performance of
the genes selected through the LCC against a list of known
candidates, [5] with the performance of all genes selected from the
GWAS at the same gene-wise P-value cutoff or the performance of
a number of GWAS top genes equal to the number of genes
encoding LCC proteins. Genes implicated in ASD are largely
unknown, thus low precision values are expectable given the
incompleteness and noise in the available knowledge in the field.
Table 1 shows that, for both datasets, genes encoding proteins
included in the LCC presented a 2 to 2.5 fold higher precision
against the list of known genes than all the GWAS genes selected
at the same statistical level cutoff. In other words, genes included
in the LCC, and thus encoding functionally related proteins, are
enriched in known candidates compared with the set of genes
selected from the GWAS at the same statistical level, demonstrat-
ing that our filtering approach of association results based on PPIs
more specifically captures ASD-relevant genes. A 1.3 to 3.3 fold
increase is observed when comparing LCC genes with the same
number of GWAS top genes, showing that a protein interaction-
based selection was more accurate than selecting only the most
strongly associated genes.
Network-Based Analysis of ASD GWAS
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Concerning the proportion of known genes that are retrieved by
our selection, or recall, LCC encoding genes had a lower recall
compared with all genes selected at the same cutoff, as expected
since LCC genes are a subset of this selection (Table 1). However,
compared with the top-gene selection, the 1.4 to 3 fold increase in
the recall achieved by LCC encoding genes, indicates that
additional relevant low effect genes are being captured. Further
inspection of the known genes present in the top gene set and the
LCC encoding genes confirmed that LCCs capture not only larger
effect genes overlapping with top genes, such as MET (Uniprot
P08581)(in AGP dataset), but additionally capture low effect genes,
such as TSC2 (Uniprot P49815), which single gene association
analysis alone does not have the power to detect.
One of the major problems in ASD GWAS and GWAS in
general is the low reproducibility of results between different
datasets. Indeed, we found only one SNP (rs11837890 in TBK1
gene) and 10 genes in common between the two datasets, when
comparing the same number of SNPs or genes (ranked by P-
values) than genes included in the LCCs from each dataset.
Remarkably, we observed a 25 and 2.5-fold increase in the overlap
between the two ASD datasets (AGP and AGRE) at PPI network
level when compared to SNP or gene level, respectively (Figure
S2).
Taken together, these results showed that our selection of
functionally connected genes based on the largest connected
component is an effective approach to capture ASD-relevant
disease candidate genes, which might escape detection in an
analysis based only on association evidence, even at gene-level.
Functionally connected genes in ASD suggest novel
susceptibility genes
Given the observation that the largest connected component
contains ASD-relevant proteins, we further explored this network
for biological processes implicated in ASD (step 5). The largest
connected components generated by genes selected at -Log10P,1
from the AGP and AGRE datasets comprised 416 and 367
proteins, respectively. A first look into the biological processes
represented in these networks, using functional enrichment
analysis, revealed an enrichment in pathways related to regulation
of apoptosis and cell cycle. Additionally, intersection of the protein
network data with knockout mice phenotypes from the Mouse
Genome Informatics Database, showed that these proteins are
primarily involved in aberrant embryogenic and developmental
processes and anomalous immune system phenotypes.
A closer inspection of these LCCs at the gene level showed that
around 30 (7–8%) of the encoding genes were implicated in
neuropsychiatric or neurodegenerative disorders (Table S2). More
interestingly, 20 (5–6%) of the LCC encoding genes were found to
carry de novo mutations in ASD described in at least one of the
three whole exome sequencing studies recently published [4,7,46],
with 3 genes overlapping between the two datasets (CSDE1
(Uniprot O75534), PGD (Uniprot P52209), TSC2). In addition, 80
Figure 2. Network properties of proteins selected at gene-wise P,0.1 in each ASD. a) Comparison of percentage of direct interactions and
isolated nodes between proteins selected at gene-wise P,0.1 in each GWAS dataset (red circles) vs 1000 random samples of network proteins
(represented by light gray and dark gray box plots, for direct interactions and isolated nodes, respectively). The bottom and top of the box represent
the 25th and 75th percentile and the extremity of the whiskers the maximum and minimum of the random samples data. b) Same comparison for the
largest connected component (LCC) size.
doi:10.1371/journal.pone.0112399.g002
Table 1. Precision and recall were consistently higher for LCC genes relative to top GWAS genes or genes selected at P,0.1.
Precision (%) Recall (%)
Gene subset AGP dataset AGRE dataset AGP dataset AGRE dataset
LCC genes 2.16 2.74 3.81 4.24
GWAS Top genes 1.68 0.82 1.27 2.97
Genes selected at P,0.1 0.96 1,11 8.47 9.43
Precision and Recall (Percentage), by ASD dataset, of three sets of genes (genes selected at a gene wise P-value cutoff of 0.1, genes included in the LCC and the same
number of GWAS top genes) against a list of known disease candidates.
doi:10.1371/journal.pone.0112399.t001
Network-Based Analysis of ASD GWAS
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(,19%) of the AGP LCC-encoding genes were deleted or
duplicated by CNVs identified by the AGP whole genome analysis
as potentially pathogenic (with less than 50% of length overlap
with control datasets) (Table S2).
To further examine the specificity of the proteins in the AGP
LCC for ASD, this network was compared with LCCs generated
from six unrelated diseases GWAS (MS, SLE, T1D, BC, NB, PD).
Based on the presence of each protein in the LCC of each
unrelated disease and in the AGRE LCC, we derived a highly
stringent ASD-specificity protein score, allowing the prioritization
of encoding genes for follow-up. Low scoring proteins were not
replicated in the AGRE dataset, and were present in one or more
unrelated diseases, whereas the highest scoring proteins were
present in both ASD LCCs, but in none of the LCCs generated
from the unrelated diseases. This analysis revealed that the
majority of proteins (,63%) were present only in the AGP
network, while 31% of the proteins were present in at least one
additional non-ASD network, and thus were not specific. From the
25 proteins identified in both ASD networks, the majority (56%)
was not present in any ASD-unrelated network and 28% were
present in one of the ASD-unrelated networks.
Using this gene scoring system, based on gene reproducibility
and specificity for ASD, we built a network with the 14 top scoring
genes and their first neighbors in the LCC network (Figure 3). The
largest component of this network, although approximately 7 times
smaller than the original LCCs, showed a similar overlap (,5%)
with genes reported to have de novo mutations in ASD (PGD,
SYNE1 (Uniprot Q8NF91), TSC2) and an increased overlap with
known candidate genes (SYNE1, TSC2 and SHANK3 (Uniprot
Q9BYB0)) and with genes contained in potentially relevant CNVs
identified by the AGP analysis (,26%). Enrichment in mouse
phenotypes was also similar but, in addition, an enrichment in
abnormal nervous system phenotype became significant, and in
abnormal behavior/neurological phenotype borderline significant.
The genes encoding the 14 top scoring proteins were considered
the best candidates for harboring common variants associated with
ASD risk (Table 2). These genes are involved in various biological
processes, such as NGF signaling, axon guidance, cell adhesion and
migration, cytoskeleton regulation, apoptosis and DNA repair. A de
novomutation in the phosphogluconate dehydrogenase gene (PGD)
has recently been reported in ASD [4], while potentially pathogenic
CNVs deleting or duplicating the ABL1 (Uniprot P00519),
RPS6KA1 (Uniprot Q15418) and PPP1CB (Uniprot P62140)
genes were identified in ASD patients from the AGP study. A query
of our genes in the NEXTBIO platform, a data mining framework
that integrates and correlates global public datasets with several
normal and disease phenotypes, revealed correlations of six genes
with ASD. For instance, deletions within the NASP (Uniprot
P49321) gene were identified in ASD patients from the Simons
Simplex Collection (SSC) [47]. An altered expression of this gene, as
well as of the NR4A1 (Uniprot P22736), ABI1 (Uniprot Q8IZP0),
BBS4 (Uniprot Q96RK4), LMNA (Uniprot P02545) and ABL1
genes, was found in postmortem brain tissue [48] or lymphoblastoid
cells [49] of ASD patients. Some of the 14 top-scoring genes, namely
the CTSB (Uniprot P07858), BBS4, LMNA and ABL1 genes, were
associated with abnormal nervous system phenotypes in animal
models. The most strongly associated genes to ASD, using the AGP
data, were the peroxiredoxin 1 gene (PRDX1 (Uniprot Q06830))
and cathepsin B gene (CTSB).
Discussion
In this study we have conducted a network-based analysis of two
ASD GWAS datasets, hypothesizing that small effect ASD risk
variants hidden at the level of GWAS statistical noise can be
discovered from networks of genes with related biological
functions. Mapping of association data to a PPI network indeed
revealed that, in both datasets, ASD-associated genes at P,0.1
encoded proteins that directly interact beyond random expecta-
tion, are more rarely found isolated in the network and are
connected in significantly larger LCCs than expected by chance,
suggesting a functional connection. These results support recent
findings from the AGP consortium, showing that stronger
association of allele scores with case status was generally achieved
when those scores were based on markers associated at significance
thresholds higher than 0.2 [8]. The International Schizophrenia
GWAS consortium had similar results of optimal discrimination
between cases and controls only after the inclusion of markers with
P-values as high as 0.2, [14] using this allele scoring approach.
The relevance to ASD of these networks was further illustrated
by their higher performance in retrieving known ASD candidates
compared to top GWAS genes, and the increased similarity
between the two ASD datasets, when compared to SNP or gene
level overlap. Remarkably, the AGP and AGRE LCCs included
20 genes, respectively, in which de novo mutations have been
described in whole-exome sequencing studies of nearly a thousand
ASD patients [4,7,50]. A large overlap of our results with the
published data of these sequencing studies was not expected,
because the LCCs encoding genes are likely to harbor variants
transmitted by unaffected parents, whereas these sequencing
studies mainly focused, and reported only, de novo variants which
do not explain the heritability of the disorder, but support recent
observations that common and rare variants associated with ASD
disturb common neuronal networks [51]. Moreover, around 20%
of the AGP LCC encoding genes were deleted or duplicated by
potentially pathogenic CNVs detected in the AGP whole genome
CNV screening of 2446 ASD patients.
As an additional filter for meaningful ASD biology, we derived
an ASD candidate gene prioritization system ranking the genes
encoding proteins included in the AGP LCC for ASD reproduc-
ibility and specificity. The scoring system used was very stringent,
in particular since some of the control disorders are neurological
(Parkinson’s, multiple sclerosis or neuroblastoma) and may share
susceptibility genes and pathways with autism [52–56]. While we
may have discarded relevant autism risk genes that are ubiquitous
and common to these disorders, we believe that we enriched our
list of genes in true positive results with a higher chance of
experimental validation. In fact, the enrichment analysis per-
formed with the top-scoring genes and their first neighbors showed
a high content in mouse genes associated with nervous system or
neurological phenotypes and a similar or higher overlap with
candidate genes or genes reported with de novo mutations or
potentially pathogenic CNVs in ASD.
This approach generated a list of 14 top-scoring genes, present
in the two ASD networks and none of the other disorders, which
were considered strong candidates to harbor common variants
associated with ASD risk. These genes are mostly novel candidates
for ASD, and are involved in nervous system pathways or other
more fundamental biological processes which have been widely
associated to ASD, such as ubiquitination [4,9,57,58], cytoskeleton
organization and regulation [5,47,59] and cell adhesion [10,60].
For instance, the CTSB, BBS4, LMNA and ABL1 genes have
been associated with neurobiological phenotypes identified in an
enrichment analysis of mouse neurobiological phenotypes from a
list of 112 ASD candidate genes [61], with CTSB and ABL1
associated with cerebellum morphological and development
abnormalities. The AGP genome-wide analysis identified poten-
tially pathogenic CNVs spanning ABL1, RPS6KA1 and
Network-Based Analysis of ASD GWAS
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PPP1CB, whose relevance needs to be further established.
Likewise, in the phosphogluconate dehydrogenase gene (PGD), a
de novo mutation has recently been reported in a patient with
ASD [4], although with an uncertain deleterious effect. This gene
plays a critical role in protecting cells from oxidative stress [62]
and, together with PRDX1, which also has an important
antioxidant protective role in cells [63,64] and shows the strongest
association with ASD, supports emerging evidence for a role of
oxidative stress in ASD pathophysiology [65,66].
Thus far the use of protein networks to address common risk
variants in ASD was limited to enrichment analysis of GWAS top
hit genes in co-expressed or differentially expressed networks
[51,67]. In contrast, this study incorporated protein interaction
data into GWAS analysis, without a priori assumptions of
association thresholds. The present results have shown that
autism-associated genes at higher than conventional levels of
significance are functionally related, and were used to extract
relevant disease biology and uncover small effect variants
contributing to the disorder. The study highlighted a group of
novel susceptibility genes relevant for CNS function with a high
probability of bearing common variants associated with autism,
which have been elusive thus far, and warranting further analysis
for identification of causal variants.
Supporting Information
Figure S1 Network properties per gene-wise P-value for
each ASD dataset. For each –Log10 gene wise association P-
value cutoff in the x-axis, the percentage of direct interactions (A)
and isolated nodes (B) and the logarithm of the LCC size (C) were
plotted for proteins encoded by disease-associated genes (red line)
and for the mean of 1000 equal sized random samples of proteins
(blue line). Dark grey areas represent the range between the 25th
and 75th quartiles and light gray areas indicate the range between
the minimum and maximum values of the random data. Empirical
P-values are indicated for each gene wise association P-value
comparison. Values are plotted until the –Log10 for which the
percentage of direct interactions and isolated nodes reaches 0 and
100%, respectively.
(TIF)
Figure S2 Overlap between the two ASD datasets at
SNP, gene or network level. Venn diagrams showing the
overlap between the two ASD datasets (AGP and AGRE) at SNP,
gene or network level.
(TIF)
Table S1 GWAS datasets used in the analysis and
genotyping platforms.
(XLSX)
Figure 3. ASD top scoring gene network. This network illustrates the 14 top scoring genes included in the ASD LCC and their first neighbors.
Nodes are colored based on a score reflecting their presence in the second ASD dataset and in the 6 unrelated diseases LCCs. A darker color
represents a higher score, which means a higher specificity for ASD.
doi:10.1371/journal.pone.0112399.g003
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Table S2 AGP LCC network genes. List of the 416 genes
included in the AGP LCC with information on gene-wise
association P-value, specificity score for ASD and previous
findings regarding implication in ASD and other neurological
disorders.
(XLSX)
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